Clinical Trial Update: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

A pediatric Phase 2/3 study evaluating subcutaneous efgartigimod alfa-ph20 for generalized myasthenia gravis in children aged 2 to under 18 is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• efgartigimod alfa-ph20 (efgartigimod alfa-ph20)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 2, Phase 3 | Status: RECRUITING